# Acutaas Chemicals share price today (Acutaas Chemicals Ltd, NSE: ACUTAAS)

> Acutaas Chemicals share price today: ₹3,777.30 at the NSE close on 4 November 2026, up 114.0% in a year. Acutaas Chemicals (NSE: ACUTAAS) is worth ₹30,922 crore, trades at a P/E of 70.4 and has closed between ₹1,648.50 and ₹4,003.60 over the past 52 weeks. > Acutaas Chemicals Ltd's earnings have grown faster than its share price. Earnings per share grew +124.5% in a year while the price moved +114.0%. ACUTAAS · Pharma - API & CRAMS · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹3,777.30 (+114.0% in a year)
- P/E: 70.4× (higher than 74% of the last 5.1 years)
- Revenue (Sep 2026): ₹437 Cr (+42.8% on a year ago)
- Profit (Sep 2026): ₹123 Cr (+70.8% on a year ago)
- Operating margin: 40.0% (+9.0 points on a year ago)
- ROCE: 32%, FY26
- Profit that came in as cash: 95%, last 3 years

The main question: promoters moved −3.3 percentage points over 8 quarters while the business went the other way. ## What is the Acutaas Chemicals share price today? Acutaas Chemicals Ltd's share price was ₹3,777.30 at the close on 4 November 2026. It has been rising for 131 weeks. That is 32.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,649 and ₹4,004, and at that close it sat 90% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 3 weeks in a row. Over the last 5.1 years the share price moved +522% while the NIFTY 500 moved +46%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Acutaas Chemicals this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), profit up on a year earlier for 9 quarters in a row and foreign funds (FIIs) raised their stake for 3 quarters in a row. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹437 crore, +42.8% on a year earlier. Why: Revenue rose because the company sold more advanced medicine intermediates. Next results: check whether new contract manufacturing orders turn into sales from more customers and products. From the earnings call on 27 Oct 2026. 2. Profit up on a year earlier for 9 quarters in a row In the September 2026 quarter profit was ₹123 crore, +70.8% on a year earlier. Why: Profit rose because more of the company's revenue came from medicine intermediates. A better product mix also helped it keep more from each sale. Next results: check if the company keeps more profit from each sale as more contract manufacturing orders are delivered. From the earnings call on 27 Oct 2026. 3. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 16.7% to 22.6% of the company by the September 2026 quarter. ## What are Acutaas Chemicals' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Acutaas Chemicals reported revenue of ₹437 crore, up 42.8% from ₹306 crore a year earlier, and a profit of ₹123 crore, up 70.8% from ₹72.0 crore. ### Acutaas Chemicals results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹437 crore | ₹306 crore | +42.8% |
| Profit | ₹123 crore | ₹72.0 crore | +70.8% |
| Earnings per share | ₹15.29 | ₹8.82 | +73.4% |
| Operating margin | 40.0% | 31.0% | +9.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Acutaas Chemicals' management discussed these results on a call held on 27 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Acutaas Chemicals share price history? Acutaas Chemicals closed at ₹3,777.30 on 4 November 2026, up 114.0% from ₹1,765.00 a year earlier (7 November 2025) and up 615.4% over five years. Its highest weekly close since September 2021 was ₹4,003.60 on 30 October 2026. ### Acutaas Chemicals share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹4,003.60 | −5.7% |
| 1 month ago · 1 Oct 2026 | ₹3,196.50 | +18.2% |
| 6 months ago · 8 May 2026 | ₹2,734.30 | +38.1% |
| 1 year ago · 7 Nov 2025 | ₹1,765.00 | +114.0% |
| 3 years ago · 3 Nov 2023 | ₹574.95 | +557.0% |
| 5 years ago · 4 Nov 2021 | ₹528.03 | +615.4% |
| Earliest weekly close in our records · 17 Sep 2021 | ₹607.58 | +521.7% |
| Highest weekly close since September 2021, also the 52-week high · 30 Oct 2026 | ₹4,003.60 | −5.7% |
| Lowest weekly close since September 2021 · 25 Feb 2022 | ₹424.30 | +790.2% |
| 52-week low (weekly close) · 19 Dec 2025 | ₹1,648.50 | +129.1% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (264 weekly closes from 17 September 2021 to 4 November 2026.)

## What is the latest news on Acutaas Chemicals? 4 Nov 2026: Acutaas Chemicals closed at ₹3,777.30, down 5.7% on the week and up 18.2% on the month. 27 Oct 2026: Acutaas Chemicals held its results call for July to September 2026. Management guided: FY27 revenue growth revised from 25% to around 30%. ### Earlier

- Results for July to September 2026: Revenue up 42.8% and profit up 70.8% on a year earlier. - 17 Sep 2026: ex-date for a dividend of ₹2.50 a share. - Our read, 22 Aug 2026: Recent earnings growth is operating-led and the newest quarter confirms commercial battery supply. The next proof points are CDMO product ramp, Product 3 commissioning and Indichem execution. - 25 Apr 2025: Share split: face value cut from ₹10 to ₹5 a share (ex-date). ### Our read of the business

Recent earnings growth is operating-led and the newest quarter confirms commercial battery supply. The next proof points are CDMO product ramp, Product 3 commissioning and Indichem execution. Latest quarter: Commercial battery supply began as revenue and profit grew against the prior-year seasonal low base. (Our read after the latest results, written 22 August 2026.)

## What dividend does Acutaas Chemicals pay? Acutaas Chemicals paid ₹2.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.07% at the ₹3,777.30 close on 4 November 2026. The last was a dividend of ₹2.50 a share, ex-date 17 September 2026. ### Acutaas Chemicals dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 17 Sep 2026 | ₹2.50 | Dividend |
| 18 Sep 2025 | ₹1.50 | Dividend |
| 13 Sep 2024 | ₹3 | Dividend |
| 18 Sep 2023 | ₹3 | Dividend |
| 29 Jul 2022 | ₹3 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Acutaas Chemicals Ltd paid out 6% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 10 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Acutaas Chemicals management say on the latest results call? On the call for July to September 2026, held on 27 October 2026, Acutaas Chemicals' management guided: FY27 revenue growth revised from 25% to around 30%. > “Here, I would like to say that the CDMO business will double in the next 3 financial years. This means that from 1,000 crore, our new target is 2,000 crore by FY30.”
> Ashwin Patel, Chairman and Managing Director, on the call for July to September 2026

### What management guided

- FY27 operating margin of 38-40%, applying to FY27 only. - CDMO revenue goal of ₹1,000 crore in FY27 and ₹2,000 crore by FY30; new contracts contribute from H2 FY27, with margins expected in the current range. - 8-9 products expected to enter revenue over 1-1.5 years; non-blockbuster molecules typically represent ₹50-100 crore for an intermediate supplier. - Battery chemicals ramp expected over 2-3 quarters on orders in hand; pricing scenario is early-teens dollars under raw-material and FX-linked repricing. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/7355-27-Oct-2026.pdf). (From the call for July to September 2026, 27 October 2026.)

## What could change the Acutaas Chemicals story? What are the risks? The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters. ### Each change stops working if

- : The validated products remain without commercial contribution through the second half of FY27. - : Commercial supply does not translate into sequential production growth over the next two reported quarters. - : Product 3 capital spending misses the latest completion date or Indichem does not show customer-commercialisation progress by the next financial year. - : Advanced pharma growth slows while battery mix rises, leaving consolidated margin below management’s stated full-year level. ### The main risks

- : Battery growth can dilute consolidated margin before CDMO contribution reaches scale. ✓ fact
- : Working capital and capital spending absorb cash during the expansion cycle. ✓ fact
- : Semiconductor and specialty recovery remains exposed to demand and customer-approval timing. ✓ fact

(Our read after the latest results, written 22 August 2026.)

## What to watch in Acutaas Chemicals' next results? When Acutaas Chemicals reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Full-year revenue and operating profit delivery against the raised framework; check whether pharma and CDMO strength continues to offset specialty softness. - What to check (from the call)
- Full-year revenue and operating profit delivery against the raised framework; check whether pharma and CDMO strength continues to offset specialty softness. - CDMO order conversion and customer/molecule breadth across the next growth leg; check whether new programs contribute without concentration. - Battery shipments and customer validation batches converting into repeat orders and broader production. - Debtor collection and working-capital days after the increase; look for stabilization in the next reported period. ## Which stock lists is Acutaas Chemicals on? Acutaas Chemicals is on 5 of our India lists: Multibagger study list, Momentum stocks, Breakout stocks, Small & mid cap stocks and Pharma stocks. - [Multibagger study list Study stage: late](https://www.sectoralpha.in/multibagger-stocks-india)
- [Momentum stocks Market cap cr: 30925.25212308922](https://www.sectoralpha.in/momentum-stocks-india)
- [Breakout stocks Breakout date: 30 October 2026](https://www.sectoralpha.in/breakout-stocks-india)
- [Small & mid cap stocks Size rank in India: 256](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 30925.25212308922](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Acutaas Chemicals profitable? Acutaas Chemicals Ltd earned ₹123 Cr of net profit in the Sep 2026 quarter, +70.8% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹356 Cr. Over 9 years profit has grown 45.7% a year on average. That is 28.1% of the quarter's revenue. The same quarter a year earlier earned ₹72.0 Cr. For the full year, FY26 profit was ₹356 Cr (+122.5% on the year before). Why profit moved: revenue changed +42.8% on a year earlier and the margin moved +9.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +97.4% and revenue +46.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Acutaas Chemicals make, and is it growing? Acutaas Chemicals Ltd reported ₹437 Cr of revenue in the Sep 2026 quarter, +42.8% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 9 years it has grown 26.6% a year on average. The last full year, FY26, came in at ₹1,339 Cr. The last four reported quarters add to ₹1,593 Cr. FY26 revenue was ₹1,339 Cr, +33.0% on the year before. Recent pace: the last four quarters grew +46.4% on average, against 26.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +45.3%, against +39.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +95.5%, against +112.5% a year (rolling over). ## How much of every ₹100 of sales does Acutaas Chemicals keep? Acutaas Chemicals Ltd's operating margin was 40.0% in the Sep 2026 quarter, 9.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 10 years it has been between 14.0% and 36.0%. The latest quarter is above every full year in that period. Why this happened. The latest call attributes gross-margin expansion to higher pharma intermediate contribution and reports advanced pharma revenue growth. This applies only if volume and mix continue while lower-margin battery capacity ramps. Why the margin moved: operating margin changed +9.2 percentage points on the year while gross margin changed +6.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Acutaas Chemicals' profit turning into cash? Over the last 3 years, 95% of Acutaas Chemicals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹292 Cr of operating cash against ₹356 Cr of profit. After ₹413 Cr of spending on assets, free cash was −₹121 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 95% of profit came in as cash: the cash cycle got 69 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 11.0× depreciation over three years. The next section checks what that spending is building. ## Where does Acutaas Chemicals' cash go? Acutaas Chemicals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 149 days in FY26, up from 80 days in FY21. It spent ₹867 Cr on assets over the last 3 years. Customers take 99 days to pay, and stock sits for 149 days on average. Why this happened. Management says the battery plant has begun commercial supply and that installed VC and FEC capacity is contracted across several customers. The ramp needs reported revenue disclosure because management did not provide a near-term contribution figure. At FY26 sales of ₹1,339 Cr, each day of that cycle ties up about ₹3.7 Cr, so roughly ₹547 Cr is tied up in the business at any time. FY26: customers took 99 days to pay and stock sat for 149 days, about 4.9 months of sales sitting as stock, for a full cycle of 149 days, longer than FY21's 80. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 149 days. Customers pay about 99 days after that. Suppliers are paid at 99 days. Together that makes the 149-day cycle. Spending on assets: ₹867 Cr over the last 3 years, against ₹79.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹332 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Acutaas Chemicals' P/E ratio, and how does it compare with its own history? Acutaas Chemicals Ltd's P/E is 70.4×, near the high end of its own history: higher than 74% of past readings. Its usual P/E (the middle reading) is 61.2×, over 5.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +124.5% while the price moved +114.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +48.2% a year; about +48.5% a year came from earnings growth and about −0.3 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 22% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What growth does the Acutaas Chemicals share price assume? Worked out from its price on 25 August 2026, Acutaas Chemicals Ltd's share price assumed profit growth of about 30.9% a year. Over the past 9 years its profit actually grew 45.7% a year. Today its P/E is 70.4×, higher than 74% of its own last 5.1 years. This is a one-day reading, taken on 25 August 2026. Every other number on this page, the multiple included, uses the latest price as of 4 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Acutaas Chemicals business getting better or worse? Acutaas Chemicals Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +228.6% at its peak to +95.5%, but the business is still expanding, with ROCE rising at 32.0%. This is based on 9 quarters of 4 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## What is the Acutaas Chemicals story, and has it been checked? Acutaas Chemicals Ltd's story is not scored yet against the checks our research set on 22 August 2026. Our read, 22 August 2026. What is proven. What is not proven yet. The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters. What would change our mind. The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters. The test written in advance. The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters. Measured by: the thesis as written as stated by the next result. What the company does. Recent earnings growth is operating-led and the newest quarter confirms commercial battery supply. The next proof points are CDMO product ramp, Product 3 commissioning and Indichem execution. Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Acutaas Chemicals management deliver what it promised? What Acutaas Chemicals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. FY27 Revenue Growth Guidance Raised · 27 October 2026. In Jul 2026, management reiterated 25% revenue growth for the full FY '27. In Oct 2026, it raised the guidance to around 30%, a material change to the full-year outlook; management cited stronger CDMO orders elsewhere on the call, but did not quantify the bridge from 25% to the company-wide 30% goal. CDMO FY27 Milestone Pulled Forward · 27 October 2026. In Apr 2026, management confirmed the existing CDMO guidance of INR1,000 crores by FY '28, and in Jul 2026 it continued to reference the INR1,000 crore goal. In Oct 2026, management moved the same milestone forward to FY27 based on current orders, which is a material change in the timing of the CDMO revenue ramp even though a broad rationale was provided. FY27 EBITDA Margin Guidance Raised · 27 October 2026. In Apr 2026 and Jul 2026, management guided that FY '27 EBITDA margins should remain broadly similar to FY '26. In Oct 2026, it instead raised FY27 guidance to 38%-40%, a material upward reset; management attributed the increase to the H2 FY27 order book and the CDMO milestone, but did not quantify the bridge from the prior margin assumption. Electrolyte Additive Phase 2 Timeline Slipped · 24 July 2026. Management moved the completion goal for the electrolyte additive Phase 2 capex from Q1 FY '27 in Apr 2026 to the end of Q2 FY27 in Jul 2026, a one-quarter delay to a major capacity milestone. The latest call calls the project on schedule but does not explain the revised date, which could affect the timing of the third product ramp-up. Every quote above is taken word for word from the company’s own earnings calls. ## How much does Acutaas Chemicals earn on its capital? Acutaas Chemicals Ltd earned a ROCE of 32% in FY26. That is up from a low of 16% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 26.6% net margin and 0.67× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 26.6% net margin × 0.67× asset turnover × 1.20× leverage (assets divided by equity) ≈ 21.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 22% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Acutaas Chemicals have too much debt? Acutaas Chemicals Ltd had ₹36.0 Cr of borrowings against ₹1,654 Cr of equity in FY26, so its debt is 0.02× its equity. Its operating profit is more than 100 times its interest bill. Over 5 years borrowings went from ₹137 Cr to ₹36.0 Cr. Over the last 3 of those years it spent ₹867 Cr on assets. The spending on assets is being paid for from cash, not new debt. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 22% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Acutaas Chemicals shareholding pattern? Foreign institutions raised their stake in Acutaas Chemicals Ltd by 8.7 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 22.6% of the company. Promoters moved −3.3 points over the same period, to 32.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +8.7 points over 8 quarters, to 22.6%; Promoters: −3.3 points over 8 quarters, to 32.7%; Domestic institutions: −0.5 points over 8 quarters, to 19.4%. Why the owners changed: foreign institutions drove it (+8.7 points), with the other side taken by promoters (−3.3 points). They raised their stake step by step. ## How far is Acutaas Chemicals from balance-sheet trouble? For Acutaas Chemicals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Acutaas Chemicals rank in its industry? 73.9 out of 100, rank 2 of 24 in Pharma - API & CRAMS, with 67% of the evidence available. Acutaas Chemicals Ltd scores 73.9 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 2. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 31.3 + 20.3 + 10.2 + 12.1 = 73.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Acutaas Chemicals compared with? Acutaas Chemicals ranks 2 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 73.9 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. Acutaas Chemicals Ltd this page ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Acutaas Chemicals in size? Acutaas Chemicals is the 6th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Gland Pharma, Anthem Biosciences and Sai Life Sciences. Just below it: Piramal Pharma, Neuland Laboratories and Granules India. ### Pharma - API & CRAMS companies close in size

1. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) ₹51,086 crore
2. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ₹46,689 crore
3. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) ₹33,093 crore
4. Acutaas Chemicals Ltd ₹32,778 crore
5. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) ₹31,807 crore
6. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) ₹25,275 crore
7. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) ₹22,907 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) ₹33,093 crore · Pharma - API & CRAMS
2. [CRISIL Ltd](https://www.sectoralpha.in/stocks/crisil-ltd) ₹33,030 crore · Credit Rating Agencies
3. Acutaas Chemicals Ltd ₹32,778 crore
4. [3M India Ltd](https://www.sectoralpha.in/stocks/3m-india-ltd) ₹32,672 crore · Diversified
5. [National Highways Infra Trust](https://www.sectoralpha.in/stocks/national-highways-infra-trust) ₹32,636 crore · Infrastructure Investment Trusts

## What else do people ask about Acutaas Chemicals? ### What is Acutaas Chemicals's share price today? Acutaas Chemicals Ltd's share price is ₹3,777.30, +114.0% over the past year. The whole company is worth ₹30,922 Cr on the market. In the last 52 weeks it traded between ₹1,649 to ₹4,004; today it is 90% of the way up from the low, 32.3% above its 200-day average (as of 4 November 2026). ### What were Acutaas Chemicals's latest quarterly results? Acutaas Chemicals Ltd reported revenue of ₹437 Cr and net profit of ₹123 Cr for the Sep 2026 quarter. Revenue rose 42.8% and profit rose 70.8% compared with a year earlier. Earnings per share were ₹15.29. The operating margin was 40.0%, 9.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Acutaas Chemicals's market cap? Acutaas Chemicals Ltd's market capitalisation is ₹30,922 Cr at a share price of ₹3,777.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Acutaas Chemicals performing? Acutaas Chemicals Ltd's share price has been rising for 131 weeks. In its latest quarter, revenue rose 42.8% and profit rose 70.8% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 3 weeks running (as of 4 November 2026). ### Will Acutaas Chemicals's share price go up? This page does not forecast Acutaas Chemicals Ltd's share price. What it shows instead: the share price is ₹3,777.30, and it has been rising for 131 weeks. Its P/E of 70.4× is higher than 74% of its own last 5 years (as of 4 November 2026). ### Who owns Acutaas Chemicals? Promoters own 32.7% of Acutaas Chemicals Ltd, foreign institutions 22.6%, domestic institutions 19.4% and the public 25.3% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 8.7 percentage points over 8 quarters (as of 4 November 2026). ### Where is Acutaas Chemicals in its business cycle? Acutaas Chemicals Ltd's FY26 operating margin was 36.0%, against a 10-year range of 14.0% to 36.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 40.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Acutaas Chemicals story? The main question: promoters moved −3.3 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Acutaas Chemicals a stock worth studying right now? What the numbers show: Acutaas Chemicals Ltd's earnings have grown faster than its share price. Earnings per share grew +124.5% in a year while the price moved +114.0%. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Acutaas Chemicals share price forecast for 2026? What management itself guided: FY27 revenue growth revised from 25% to around 30%. What would change the story: The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters. ## Lists

- Multibagger study list: https://www.sectoralpha.in/multibagger-stocks-india
- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Breakout stocks: https://www.sectoralpha.in/breakout-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.